Related Experiment Videos

[Consequences of clinical genetic analysis of RET proto-oncogene]

J Włoch1, Z Wygoda, M Wiench

  • 1Kliniki Chirurgii Onkologicznej, Centrum Onkologii-Instytut im. M. Skłodowskiej-Curie, Oddział w Gliwicach.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|August 17, 2002
PubMed

Insights

Genetic analysis identifies RET protooncogene mutations in hereditary medullary thyroid carcinoma. Early detection in asymptomatic carriers allows timely intervention, normalizing calcitonin levels and guiding surgical decisions.

Area of Science:

  • Oncology
  • Genetics
  • Endocrinology

Background:

  • Hereditary medullary thyroid carcinoma (MTC) is often linked to RET protooncogene mutations.
  • Early diagnosis is crucial for effective management and improved patient outcomes.
  • Genetic screening plays a vital role in identifying at-risk individuals.

Purpose of the Study:

  • To present preliminary findings on the treatment of inherited medullary thyroid carcinoma.
  • To highlight the impact of genetic analysis in diagnosing MTC.
  • To demonstrate how genetic results influence clinical decisions regarding surgery and further diagnostics.

Main Methods:

  • Genetic analysis to detect RET protooncogene mutations.
  • Clinical evaluation of patients identified as mutation carriers.
  • Preoperative and postoperative monitoring of calcitonin levels.
  • Correlation of genetic findings with clinical presentation and surgical management.

Main Results:

  • Out of 16 identified RET mutation carriers, 4 had clinically evident MTC and 12 were asymptomatic.
  • Normalization of elevated preoperative calcitonin levels was achieved in all treated patients.
  • Genetic findings guided decisions on the extent and timing of thyroid and lymph node surgery.
  • Diagnostic procedures for pheochromocytoma and parathyroid hyperplasia were tailored based on mutation type.

Conclusions:

  • Genetic screening for RET mutations is effective in identifying individuals with hereditary MTC.
  • Early detection and intervention in asymptomatic carriers can lead to successful treatment outcomes.
  • Multidisciplinary collaboration between geneticists and clinicians is essential for optimal MTC management.

Related Concept Videos